Adding GlaxoSmithKline's drug respiratory drug Advair to Pfizer's Spiriva does not reduce exacerbations in patients with COPD, or smokers lung, according to new research.
Canadian researchers said giving Advair on top of Spiriva did not affect the number of exacerbations; the main end point of the trial.
The study, published in Annals of Internal Medicine, involved 449 adults with moderate or severe chronic obstructive pulmonary disease (COPD).
Reuters
No comments:
Post a Comment